Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · January 07, 2015

2014 Top Stories in Oncology: Survival Results From the CLEOPATRA Trial in HER2+ Breast Cancer

Lee Schwartzberg MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012; 366(2):109-119.

  2. Swain S, Kim S-B, Cortes J, et al. Final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. Paper presented at: ESMO 2014, European Society for Medical Oncology Annual Congress; September 26-30, 2014; Madrid, Spain. Abstract 350O_PR.

Disclosure statements are available on the authors' profiles:

Lee Schwartzberg MD, FACP

Further Reading

Most Read This Week

Recently Updated